High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target

Journal of Medicinal Chemistry

Volumn 61, Issue 12, 2018, Pages 5093-5107

  Vanpatten, Sonya ^a   Al Abed, Yousef ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; ALARMIN; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN;

DRUG TARGETING; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIMIT OF QUANTITATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES;

ALARMINS; BIOMARKERS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MOLECULAR TARGETED THERAPY; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES;

EID: 85046596151     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b01136     Document Type: Review

References (176)

1. Sirisinha, S. Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J. Allergy Immunol. 2011, 29 (1), 1-14
2. Liston, A.; Masters, S. L. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat. Rev. Immunol. 2017, 17 (3), 208-214, 10.1038/nri.2016.151
3. Serhan, C. N. Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. FASEB J. 2017, 31 (4), 1273-1288, 10.1096/fj.201601222R
4. Buckley, C. D.; Gilroy, D. W.; Serhan, C. N.; Stockinger, B.; Tak, P. P. The resolution of inflammation. Nat. Rev. Immunol. 2013, 13 (1), 59-66, 10.1038/nri3362
5. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J. M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K. R.; Faist, E.; Abraham, E.; Andersson, J.; Andersson, U.; Molina, P. E.; Abumrad, N. N.; Sama, A.; Tracey, K. J. Hmg-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285 (5425), 248-251
6. Thomas, J. O. HMG1 and 2: Architectural DNA-binding proteins. Biochem. Soc. Trans. 2001, 29 (4), 395-401, 10.1042/bst0290395
7. Zhu, X.; Messer, J. S.; Wang, Y.; Lin, F.; Cham, C. M.; Chang, J.; Billiar, T. R.; Lotze, M. T.; Boone, D. L.; Chang, E. B. Cytosolic hmgb1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J. Clin. Invest. 2015, 125 (3), 1098-1110, 10.1172/JCI76344
8. Yanai, H.; Ban, T.; Wang, Z.; Choi, M. K.; Kawamura, T.; Negishi, H.; Nakasato, M.; Lu, Y.; Hangai, S.; Koshiba, R.; Savitsky, D.; Ronfani, L.; Akira, S.; Bianchi, M. E.; Honda, K.; Tamura, T.; Kodama, T.; Taniguchi, T. Hmgb proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462 (7269), 99-103, 10.1038/nature08512
9. Yang, H.; Wang, H.; Tracey, K. J. Hmg-1 rediscovered as a cytokine. Shock 2001, 15 (4), 247-253, 10.1097/00024382-200115040-00001
10. Calogero, S.; Grassi, F.; Aguzzi, A.; Voigtlander, T.; Ferrier, P.; Ferrari, S.; Bianchi, M. E. The lack of chromosomal protein hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 1999, 22 (3), 276-280, 10.1038/10338
11. Tang, D.; Kang, R.; Van Houten, B.; Zeh, H. J.; Billiar, T. R.; Lotze, M. T. High mobility group box 1 (hmgb1) phenotypic role revealed with stress. Mol. Med. 2014, 20, 359-362, 10.2119/molmed.2014.00063
12. Kang, R.; Chen, R.; Zhang, Q.; Hou, W.; Wu, S.; Cao, L.; Huang, J.; Yu, Y.; Fan, X. G.; Yan, Z.; Sun, X.; Wang, H.; Wang, Q.; Tsung, A.; Billiar, T. R.; Zeh, H. J., 3rd; Lotze, M. T.; Tang, D. Hmgb1 in health and disease. Mol. Aspects Med. 2014, 40, 1-116, 10.1016/j.mam.2014.05.001
13. Tang, D.; Billiar, T. R.; Lotze, M. T. A janus tale of two active high mobility group box 1 (hmgb1) redox states. Mol. Med. 2012, 18, 1360-1362
14. Yang, H.; Wang, H.; Chavan, S. S.; Andersson, U. High mobility group box protein 1 (hmgb1): The prototypical endogenous danger molecule. Mol. Med. 2015, 21 (Suppl. 1), S6-S12, 10.2119/molmed.2015.00087
15. Shiraki, R.; Inoue, N.; Kawasaki, S.; Takei, A.; Kadotani, M.; Ohnishi, Y.; Ejiri, J.; Kobayashi, S.; Hirata, K.; Kawashima, S.; Yokoyama, M. Expression of toll-like receptors on human platelets. Thromb. Res. 2004, 113 (6), 379-385, 10.1016/j.thromres.2004.03.023
16. Fuentes, E.; Rojas, A.; Palomo, I. Role of multiligand/rage axis in platelet activation. Thromb. Res. 2014, 133 (3), 308-314, 10.1016/j.thromres.2013.11.007
17. Newton, K.; Dixit, V. M. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect. Biol. 2012, 4 (3), a006049, 10.1101/cshperspect.a006049
18. Rouhiainen, A.; Imai, S.; Rauvala, H.; Parkkinen, J. Occurrence of amphoterin (hmg1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000, 84 (6), 1087-1094
19. Jorch, S. K.; Kubes, P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat. Med. 2017, 23 (3), 279-287, 10.1038/nm.4294
20. Ye, R. D.; Sun, L. Emerging functions of serum amyloid a in inflammation. J. Leukocyte Biol. 2015, 98 (6), 923-929, 10.1189/jlb.3VMR0315-080R
21. Agrawal, A.; Singh, P. P.; Bottazzi, B.; Garlanda, C.; Mantovani, A. Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 2009, 653, 98-116, 10.1007/978-1-4419-0901-5-7
22. Xavier, A. M.; Anunciato, A. K.; Rosenstock, T. R.; Glezer, I. Gene expression control by glucocorticoid receptors during innate immune responses. Front. Endocrinol. (Lausanne, Switz.) 2016, 7, 31, 10.3389/fendo.2016.00031
23. Andersson, U.; Wang, H.; Palmblad, K.; Aveberger, A. C.; Bloom, O.; Erlandsson-Harris, H.; Janson, A.; Kokkola, R.; Zhang, M.; Yang, H.; Tracey, K. J. High mobility group 1 protein (hmg-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000, 192 (4), 565-570, 10.1084/jem.192.4.565
24. Bianchi, M. E.; Manfredi, A. A. High-mobility group box 1 (hmgb1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 2007, 220, 35-46, 10.1111/j.1600-065X.2007.00574.x
25. Manfredi, A. A.; Capobianco, A.; Bianchi, M. E.; Rovere-Querini, P. Regulation of dendritic- and t-cell fate by injury-associated endogenous signals. Crit Rev. Immunol. 2009, 29 (1), 69-86, 10.1615/CritRevImmunol.v29.i1.30
26. Serhan, C. N. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol. Aspects Med. 2017, 58, 1-11, 10.1016/j.mam.2017.03.001
27. Strebovsky, J.; Walker, P.; Dalpke, A. H. Suppressor of cytokine signaling proteins as regulators of innate immune signaling. Front. Biosci., Landmark Ed. 2012, 17, 1627-1639, 10.2741/4008
28. Cain, D. W.; Cidlowski, J. A. Specificity and sensitivity of glucocorticoid signaling in health and disease. Best Pract Res. Clin Endocrinol Metab. 2015, 29 (4), 545-556, 10.1016/j.beem.2015.04.007
29. Huston, J. M. The vagus nerve and the inflammatory reflex: Wandering on a new treatment paradigm for systemic inflammation and sepsis. Surg Infect (Larchmt) 2012, 13 (4), 187-193, 10.1089/sur.2012.126
30. Chen, W.; Ma, X.; Zhang, P.; Li, Q.; Liang, X.; Liu, J. Mir-212-3p inhibits lps-induced inflammatory response through targeting hmgb1 in murine macrophages. Exp. Cell Res. 2017, 350 (2), 318-326, 10.1016/j.yexcr.2016.12.008
31. Zhang, L.; Wang, Y.; Ma, J.; Lai, X.; Fang, J.; Li, G.; Xu, L.; Pan, G.; Chen, Z. Exogenous mscs ameliorate hypoxia/reoxygenation injury in renal tubular epithelial cells through jak/stat signaling pathway-mediated regulation of hmgb1. Am. J. Transl. Res. 2017, 9 (5), 2412-2420
32. Czura, C. J.; Friedman, S. G.; Tracey, K. J. Neural inhibition of inflammation: The cholinergic anti-inflammatory pathway. J. Endotoxin Res. 2003, 9 (6), 409-413, 10.1177/09680519030090060401
33. Fullerton, J. N.; Gilroy, D. W. Resolution of inflammation: A new therapeutic frontier. Nat. Rev. Drug Discovery 2016, 15 (8), 551-567, 10.1038/nrd.2016.39
34. Venereau, E.; Casalgrandi, M.; Schiraldi, M.; Antoine, D. J.; Cattaneo, A.; De Marchis, F.; Liu, J.; Antonelli, A.; Preti, A.; Raeli, L.; Shams, S. S.; Yang, H.; Varani, L.; Andersson, U.; Tracey, K. J.; Bachi, A.; Uguccioni, M.; Bianchi, M. E. Mutually exclusive redox forms of hmgb1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 2012, 209 (9), 1519-1528, 10.1084/jem.20120189
35. Ito, I.; Fukazawa, J.; Yoshida, M. Post-translational methylation of high mobility group box 1 (hmgb1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 2007, 282 (22), 16336-16344, 10.1074/jbc.M608467200
36. Oh, Y. J.; Youn, J. H.; Ji, Y.; Lee, S. E.; Lim, K. J.; Choi, J. E.; Shin, J. S. Hmgb1 is phosphorylated by classical protein kinase c and is secreted by a calcium-dependent mechanism. J. Immunol. 2009, 182 (9), 5800-5809, 10.4049/jimmunol.0801873
37. Andersson, U.; Antoine, D. J.; Tracey, K. J. The functions of hmgb1 depend on molecular localization and post-translational modifications. J. Intern. Med. 2014, 276 (5), 420-424, 10.1111/joim.12309
38. Yu, Y.; Tang, D.; Kang, R. Oxidative stress-mediated hmgb1 biology. Front. Physiol. 2015, 6, 93, 10.3389/fphys.2015.00093
39. LeBlanc, P. M.; Doggett, T. A.; Choi, J.; Hancock, M. A.; Durocher, Y.; Frank, F.; Nagar, B.; Ferguson, T. A.; Saleh, M. An immunogenic peptide in the a-box of hmgb1 protein reverses apoptosis-induced tolerance through rage receptor. J. Biol. Chem. 2014, 289 (11), 7777-7786, 10.1074/jbc.M113.541474
40. Zhang, T.; Wei, W.; Dirsch, O.; Kruger, T.; Kan, C.; Xie, C.; Kniemeyer, O.; Fang, H.; Settmacher, U.; Dahmen, U. Identification of proteins interacting with cytoplasmic high-mobility group box 1 during the hepatocellular response to ischemia reperfusion injury. Int. J. Mol. Sci. 2017, 18 (1), 167, 10.3390/ijms18010167
41. Chen, G. Y.; Tang, J.; Zheng, P.; Liu, Y. Cd24 and siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323 (5922), 1722-1725, 10.1126/science.1168988
42. Salmivirta, M.; Rauvala, H.; Elenius, K.; Jalkanen, M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp. Cell Res. 1992, 200 (2), 444-451, 10.1016/0014-4827(92)90194-D
43. Orlova, V. V.; Choi, E. Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C. M.; Gahmberg, C. G.; Bianchi, M. E.; Nawroth, P. P.; Chavakis, T. A novel pathway of hmgb1-mediated inflammatory cell recruitment that requires mac-1-integrin. EMBO J. 2007, 26 (4), 1129-1139, 10.1038/sj.emboj.7601552
44. Yu, M.; Wang, H.; Ding, A.; Golenbock, D. T.; Latz, E.; Czura, C. J.; Fenton, M. J.; Tracey, K. J.; Yang, H. Hmgb1 signals through toll-like receptor (tlr) 4 and tlr2. Shock 2006, 26 (2), 174-179, 10.1097/01.shk.0000225404.51320.82
45. Li, Y. H.; Kuo, C. H.; Shi, G. Y.; Wu, H. L. The role of thrombomodulin lectin-like domain in inflammation. J. Biomed. Sci. 2012, 19, 34, 10.1186/1423-0127-19-34
46. Yang, H.; Wang, H.; Wang, Y.; Addorisio, M.; Li, J.; Postiglione, M. J.; Chavan, S. S.; Al-Abed, Y.; Antoine, D. J.; Andersson, U.; Tracey, K. J. The haptoglobin beta subunit sequesters hmgb1 toxicity in sterile and infectious inflammation. J. Intern. Med. 2017, 282 (1), 76-93, 10.1111/joim.12619
47. Swart, C.; Du Toit, A.; Loos, B. Autophagy and the invisible line between life and death. Eur. J. Cell Biol. 2016, 95 (12), 598-610, 10.1016/j.ejcb.2016.10.005
48. Krebs, J.; Agellon, L. B.; Michalak, M. Ca(2+) homeostasis and endoplasmic reticulum (er) stress: An integrated view of calcium signaling. Biochem. Biophys. Res. Commun. 2015, 460 (1), 114-121, 10.1016/j.bbrc.2015.02.004
49. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Calcium and mitochondria in the regulation of cell death. Biochem. Biophys. Res. Commun. 2015, 460 (1), 72-81, 10.1016/j.bbrc.2015.01.137
50. Ma, L.; Kim, S. J.; Oh, K. I. Calcium/calmodulin-dependent protein kinase is involved in the release of high mobility group box 1 via the interferon-beta signaling pathway. Immune Netw. 2012, 12 (4), 148-154, 10.4110/in.2012.12.4.148
51. Zhang, X.; Wheeler, D.; Tang, Y.; Guo, L.; Shapiro, R. A.; Ribar, T. J.; Means, A. R.; Billiar, T. R.; Angus, D. C.; Rosengart, M. R. Calcium/calmodulin-dependent protein kinase (camk) iv mediates nucleocytoplasmic shuttling and release of hmgb1 during lipopolysaccharide stimulation of macrophages. J. Immunol. 2008, 181 (7), 5015-5023, 10.4049/jimmunol.181.7.5015
52. Zhang, C.; Mo, M.; Ding, W.; Liu, W.; Yan, D.; Deng, J.; Luo, X.; Liu, J. High-mobility group box 1 (hmgb1) impaired cardiac excitation-contraction coupling by enhancing the sarcoplasmic reticulum (sr) ca(2+) leak through tlr4-ros signaling in cardiomyocytes. J. Mol. Cell. Cardiol. 2014, 74, 260-273, 10.1016/j.yjmcc.2014.06.003
53. Tang, S.; Chen, T.; Yang, M.; Wang, L.; Yu, Z.; Xie, B.; Qian, C.; Xu, S.; Li, N.; Cao, X.; Wang, J. Extracellular calcium elicits feedforward regulation of the toll-like receptor-triggered innate immune response. Cell. Mol. Immunol. 2017, 14 (2), 180-191, 10.1038/cmi.2015.59
54. Ren, H.; Teng, Y.; Tan, B.; Zhang, X.; Jiang, W.; Liu, M.; Jiang, W.; Du, B.; Qian, M. Toll-like receptor-triggered calcium mobilization protects mice against bacterial infection through extracellular atp release. Infect. Immun. 2014, 82 (12), 5076-5085, 10.1128/IAI.02546-14
55. de Bernard, M.; Rizzuto, R. Toll-like receptors hit calcium. EMBO Rep. 2014, 15 (5), 468-469, 10.1002/embr.201438685
56. Allette, Y. M.; Due, M. R.; Wilson, S. M.; Feldman, P.; Ripsch, M. S.; Khanna, R.; White, F. A. Identification of a functional interaction of hmgb1 with receptor for advanced glycation end-products in a model of neuropathic pain. Brain, Behav., Immun. 2014, 42, 169-177, 10.1016/j.bbi.2014.06.199
57. Schiraldi, M.; Raucci, A.; Munoz, L. M.; Livoti, E.; Celona, B.; Venereau, E.; Apuzzo, T.; De Marchis, F.; Pedotti, M.; Bachi, A.; Thelen, M.; Varani, L.; Mellado, M.; Proudfoot, A.; Bianchi, M. E.; Uguccioni, M. Hmgb1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with cxcl12 and signaling via cxcr4. J. Exp. Med. 2012, 209 (3), 551-563, 10.1084/jem.20111739
58. Han, H.; Yi, F. New insights into trp channels: Interaction with pattern recognition receptors. Channels 2014, 8 (1), 13-19, 10.4161/chan.27178
59. Stevens, N. E.; Chapman, M. J.; Fraser, C. K.; Kuchel, T. R.; Hayball, J. D.; Diener, K. R. Therapeutic targeting of hmgb1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci. Rep. 2017, 7 (1), 5850, 10.1038/s41598-017-06205-z
60. Wang, H.; Ward, M. F.; Sama, A. E. Targeting hmgb1 in the treatment of sepsis. Expert Opin. Ther. Targets 2014, 18 (3), 257-268, 10.1517/14728222.2014.863876
61. Andersson, U.; Harris, H. E. The role of hmgb1 in the pathogenesis of rheumatic disease. Biochim. Biophys. Acta, Gene Regul. Mech. 2010, 1799 (1-2), 141-148, 10.1016/j.bbagrm.2009.11.003
62. Musumeci, D.; Roviello, G. N.; Montesarchio, D. An overview on hmgb1 inhibitors as potential therapeutic agents in hmgb1-related pathologies. Pharmacol. Ther. 2014, 141 (3), 347-357, 10.1016/j.pharmthera.2013.11.001
63. Musumeci, D.; Bucci, E. M.; Roviello, G. N.; Sapio, R.; Valente, M.; Moccia, M.; Bianchi, M. E.; Pedone, C. DNA-based strategies for blocking hmgb1 cytokine activity: Design, synthesis and preliminary in vitro/in vivo assays of DNA and DNA-like duplexes. Mol. BioSyst. 2011, 7 (5), 1742-1752, 10.1039/c1mb05009e
64. Pusterla, T.; de Marchis, F.; Palumbo, R.; Bianchi, M. E. High mobility group b2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group b1. Autoimmunity 2009, 42 (4), 308-310, 10.1080/08916930902831845
65. He, Y. H.; Wang, X. Q.; Zhang, J.; Liu, Z. H.; Pan, W. Q.; Shen, Y.; Zhu, Z. B.; Wang, L. J.; Yan, X. X.; Yang, K.; Zhang, R. Y.; Shen, W. F.; Ding, F. H.; Lu, L. Association of serum hmgb2 levels with in-stent restenosis: Hmgb2 promotes neointimal hyperplasia in mice with femoral artery injury and proliferation and migration of vsmcs. Arterioscler., Thromb., Vasc. Biol. 2017, 37 (4), 717-729, 10.1161/ATVBAHA.116.308210
66. Liu, Z. H.; Dai, D. P.; Ding, F. H.; Pan, W. Q.; Fang, Y. H.; Zhang, Q.; Li, M.; Yang, P.; Wang, X. Q.; Shen, Y.; Wang, L. J.; Yan, X. X.; He, Y. H.; Yang, K.; Zhang, R. Y.; Shen, W. F.; Chen, Y.; Lu, L. Association of serum hmgb2 level with mace at 1 mo of myocardial infarction: Aggravation of myocardial ischemic injury in rats by hmgb2 via ros. Am. J. Physiol Heart Circ Physiol. 2017, 312 (3), H422-H436, 10.1152/ajpheart.00249.2016
67. Cai, X.; Ding, H.; Liu, Y.; Pan, G.; Li, Q.; Yang, Z.; Liu, W. Expression of hmgb2 indicates worse survival of patients and is required for the maintenance of warburg effect in pancreatic cancer. Acta Biochim. Biophys. Sin. 2017, 49 (2), 119-127, 10.1093/abbs/gmw124
68. Lee, S.; Nam, Y.; Koo, J. Y.; Lim, D.; Park, J.; Ock, J.; Kim, J.; Suk, K.; Park, S. B. A small molecule binding hmgb1 and hmgb2 inhibits microglia-mediated neuroinflammation. Nat. Chem. Biol. 2014, 10 (12), 1055-1060, 10.1038/nchembio.1669
69. Mollica, L.; De Marchis, F.; Spitaleri, A.; Dallacosta, C.; Pennacchini, D.; Zamai, M.; Agresti, A.; Trisciuoglio, L.; Musco, G.; Bianchi, M. E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 2007, 14 (4), 431-441, 10.1016/j.chembiol.2007.03.007
70. Ling, Y.; Yang, Z. Y.; Yin, T.; Li, L.; Yuan, W. W.; Wu, H. S.; Wang, C. Y. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int. Immunopharmacol. 2011, 11 (2), 187-193, 10.1016/j.intimp.2010.11.014
71. Rauvala, H.; Pihlaskari, R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem. 1987, 262 (34), 16625-16635
72. Kuroiwa, Y.; Takakusagi, Y.; Kusayanagi, T.; Kuramochi, K.; Imai, T.; Hirayama, T.; Ito, I.; Yoshida, M.; Sakaguchi, K.; Sugawara, F. Identification and characterization of the direct interaction between methotrexate (mtx) and high-mobility group box 1 (hmgb1) protein. PLoS One 2013, 8 (5), e63073, 10.1371/journal.pone.0063073
73. Cho, W.; Koo, J. Y.; Park, Y.; Oh, K.; Lee, S.; Song, J. S.; Bae, M. A.; Lim, D.; Lee, D. S.; Park, S. B. Treatment of sepsis pathogenesis with high mobility group box protein 1-regulating anti-inflammatory agents. J. Med. Chem. 2017, 60 (1), 170-179, 10.1021/acs.jmedchem.6b00954
74. Choi, H. W.; Tian, M.; Song, F.; Venereau, E.; Preti, A.; Park, S. W.; Hamilton, K.; Swapna, G. V.; Manohar, M.; Moreau, M.; Agresti, A.; Gorzanelli, A.; De Marchis, F.; Wang, H.; Antonyak, M.; Micikas, R. J.; Gentile, D. R.; Cerione, R. A.; Schroeder, F. C.; Montelione, G. T.; Bianchi, M. E.; Klessig, D. F. Aspirin's active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses. Mol. Med. 2015, 21, 526-535, 10.2119/molmed.2015.00148
75. Li, W.; Ashok, M.; Li, J.; Yang, H.; Sama, A. E.; Wang, H. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting hmgb1. PLoS One 2007, 2 (11), e1153, 10.1371/journal.pone.0001153
76. Li, W.; Zhu, S.; Li, J.; Assa, A.; Jundoria, A.; Xu, J.; Fan, S.; Eissa, N. T.; Tracey, K. J.; Sama, A. E.; Wang, H. Egcg stimulates autophagy and reduces cytoplasmic hmgb1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 2011, 81 (9), 1152-1163, 10.1016/j.bcp.2011.02.015
77. Meng, X. Y.; Li, B.; Liu, S.; Kang, H.; Zhao, L.; Zhou, R. Egcg in green tea induces aggregation of hmgb1 protein through large conformational changes with polarized charge redistribution. Sci. Rep. 2016, 6, 22128, 10.1038/srep22128
78. Horiuchi, T.; Sakata, N.; Narumi, Y.; Kimura, T.; Hayashi, T.; Nagano, K.; Liu, K.; Nishibori, M.; Tsukita, S.; Yamada, T.; Katagiri, H.; Shirakawa, R.; Horiuchi, H. Metformin directly binds the alarmin hmgb1 and inhibits its proinflammatory activity. J. Biol. Chem. 2017, 292 (20), 8436-8446, 10.1074/jbc.M116.769380
79. Yang, H.; Wang, H.; Ju, Z.; Ragab, A. A.; Lundback, P.; Long, W.; Valdes-Ferrer, S. I.; He, M.; Pribis, J. P.; Li, J.; Lu, B.; Gero, D.; Szabo, C.; Antoine, D. J.; Harris, H. E.; Golenbock, D. T.; Meng, J.; Roth, J.; Chavan, S. S.; Andersson, U.; Billiar, T. R.; Tracey, K. J.; Al-Abed, Y. Md-2 is required for disulfide hmgb1-dependent tlr4 signaling. J. Exp. Med. 2015, 212 (1), 5-14, 10.1084/jem.20141318
80. Plociennikowska, A.; Hromada-Judycka, A.; Borzecka, K.; Kwiatkowska, K. Co-operation of tlr4 and raft proteins in lps-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 2015, 72 (3), 557-581, 10.1007/s00018-014-1762-5
81. Hreggvidsdottir, H. S.; Lundberg, A. M.; Aveberger, A. C.; Klevenvall, L.; Andersson, U.; Harris, H. E. High mobility group box protein 1 (hmgb1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 2012, 18, 224-230, 10.2119/molmed.2011.00327
82. Ibrahim, Z. A.; Armour, C. L.; Phipps, S.; Sukkar, M. B. Rage and tlrs: Relatives, friends or neighbours?. Mol. Immunol. 2013, 56 (4), 739-744, 10.1016/j.molimm.2013.07.008
83. Peri, F.; Calabrese, V. Toll-like receptor 4 (tlr4) modulation by synthetic and natural compounds: An update. J. Med. Chem. 2014, 57 (9), 3612-3622, 10.1021/jm401006s
84. Bongarzone, S.; Savickas, V.; Luzi, F.; Gee, A. D. Targeting the receptor for advanced glycation endproducts (rage): A medicinal chemistry perspective. J. Med. Chem. 2017, 60 (17), 7213-7232, 10.1021/acs.jmedchem.7b00058
85. Sturchler, E.; Galichet, A.; Weibel, M.; Leclerc, E.; Heizmann, C. W. Site-specific blockade of rage-vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 2008, 28 (20), 5149-5158, 10.1523/JNEUROSCI.4878-07.2008
86. Finlay, W. J.; Cunningham, O.; Lambert, M. A.; Darmanin-Sheehan, A.; Liu, X.; Fennell, B. J.; Mahon, C. M.; Cummins, E.; Wade, J. M.; O'Sullivan, C. M.; Tan, X. Y.; Piche, N.; Pittman, D. D.; Paulsen, J.; Tchistiakova, L.; Kodangattil, S.; Gill, D.; Hufton, S. E. Affinity maturation of a humanized rat antibody for anti-rage therapy: Comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J. Mol. Biol. 2009, 388 (3), 541-558, 10.1016/j.jmb.2009.03.019
87. Wang, X.; Smith, C.; Yin, H. Targeting toll-like receptors with small molecule agents. Chem. Soc. Rev. 2013, 42 (12), 4859-4866, 10.1039/c3cs60039d
88. Patra, M. C.; Choi, S. Recent progress in the development of toll-like receptor (tlr) antagonists. Expert Opin. Ther. Pat. 2016, 26 (6), 719-730, 10.1080/13543776.2016.1185415
89. Achek, A.; Yesudhas, D.; Choi, S. Toll-like receptors: Promising therapeutic targets for inflammatory diseases. Arch. Pharmacal Res. 2016, 39 (8), 1032-1049, 10.1007/s12272-016-0806-9
90. Jules, J.; Maiguel, D.; Hudson, B. I. Alternative splicing of the rage cytoplasmic domain regulates cell signaling and function. PLoS One 2013, 8 (11), e78267, 10.1371/journal.pone.0078267
91. Kew, R. R.; Penzo, M.; Habiel, D. M.; Marcu, K. B. The ikkalpha-dependent nf-kappab p52/relb noncanonical pathway is essential to sustain a cxcl12 autocrine loop in cells migrating in response to hmgb1. J. Immunol. 2012, 188 (5), 2380-2386, 10.4049/jimmunol.1102454
92. van Hout, A.; D'huys, T.; Oeyen, M.; Schols, D.; Van Loy, T. Comparison of cell-based assays for the identification and evaluation of competitive cxcr4 inhibitors. PLoS One 2017, 12 (4), e0176057, 10.1371/journal.pone.0176057
93. Bongartz, T.; Sutton, A. J.; Sweeting, M. J.; Buchan, I.; Matteson, E. L.; Montori, V. Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295 (19), 2275-2285, 10.1001/jama.295.19.2275
94. Minozzi, S.; Bonovas, S.; Lytras, T.; Pecoraro, V.; Gonzalez-Lorenzo, M.; Bastiampillai, A. J.; Gabrielli, E. M.; Lonati, A. C.; Moja, L.; Cinquini, M.; Marino, V.; Matucci, A.; Milano, G. M.; Tocci, G.; Scarpa, R.; Goletti, D.; Cantini, F. Risk of infections using anti-tnf agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Expert Opin. Drug Saf. 2016, 15 (sup1), 11-34, 10.1080/14740338.2016.1240783
95. Urbonaviciute, V.; Furnrohr, B. G.; Weber, C.; Haslbeck, M.; Wilhelm, S.; Herrmann, M.; Voll, R. E. Factors masking hmgb1 in human serum and plasma. J. Leukocyte Biol. 2007, 81 (1), 67-74, 10.1189/jlb.0306196
96. Bults, P.; van de Merbel, N. C.; Bischoff, R. Quantification of biopharmaceuticals and biomarkers in complex biological matrices: A comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays. Expert Rev. Proteomics 2015, 12 (4), 355-374, 10.1586/14789450.2015.1050384
97. Izrael-Tomasevic, A.; Phu, L.; Phung, Q. T.; Lill, J. R.; Arnott, D. Targeting interferon alpha subtypes in serum: A comparison of analytical approaches to the detection and quantitation of proteins in complex biological matrices. J. Proteome Res. 2009, 8 (6), 3132-3140, 10.1021/pr900076q
98. Festoff, B. W.; Sajja, R. K.; van Dreden, P.; Cucullo, L. Hmgb1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. J. Neuroinflammation 2016, 13 (1), 194, 10.1186/s12974-016-0670-z
99. Nilson, A. N.; English, K. C.; Gerson, J. E.; Barton Whittle, T.; Nicolas Crain, C.; Xue, J.; Sengupta, U.; Castillo-Carranza, D. L.; Zhang, W.; Gupta, P.; Kayed, R. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J. Alzheimer's Dis. 2017, 55 (3), 1083-1099, 10.3233/JAD-160912
100. Takata, K.; Kitamura, Y.; Kakimura, J.; Shibagaki, K.; Tsuchiya, D.; Taniguchi, T.; Smith, M. A.; Perry, G.; Shimohama, S. Role of high mobility group protein-1 (hmg1) in amyloid-beta homeostasis. Biochem. Biophys. Res. Commun. 2003, 301 (3), 699-703, 10.1016/S0006-291X(03)00024-X
101. Casula, M.; Iyer, A. M.; Spliet, W. G.; Anink, J. J.; Steentjes, K.; Sta, M.; Troost, D.; Aronica, E. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011, 179, 233-243, 10.1016/j.neuroscience.2011.02.001
102. Juranek, J. K.; Daffu, G. K.; Wojtkiewicz, J.; Lacomis, D.; Kofler, J.; Schmidt, A. M. Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2015, 9, 485, 10.3389/fncel.2015.00485
103. Sun, X. H.; Liu, Y.; Han, Y.; Wang, J. Expression and significance of high-mobility group protein b1 (hmgb1) and the receptor for advanced glycation end-product (rage) in knee osteoarthritis. Med. Sci. Monit. 2016, 22, 2105-2112, 10.12659/MSM.895689
104. Ke, X.; Jin, G.; Yang, Y.; Cao, X.; Fang, R.; Feng, X.; Lei, B. Synovial fluid hmgb-1 levels are associated with osteoarthritis severity. Clin. Lab. 2015, 61 (7), 809-818, 10.7754/Clin.Lab.2015.141205
105. Amin, A. R.; Islam, A. B. Genomic analysis and differential expression of hmg and s100a family in human arthritis: Upregulated expression of chemokines, il-8 and nitric oxide by hmgb1. DNA Cell Biol. 2014, 33 (8), 550-565, 10.1089/dna.2013.2198
106. Pullerits, R.; Schierbeck, H.; Uibo, K.; Liivamagi, H.; Tarraste, S.; Talvik, T.; Sundberg, E.; Pruunsild, C. High mobility group box protein 1-a prognostic marker for structural joint damage in 10-year follow-up of patients with juvenile idiopathic arthritis. Semin. Arthritis Rheum. 2017, 46 (4), 444-450, 10.1016/j.semarthrit.2016.08.017
107. Taniguchi, N.; Kawahara, K.; Yone, K.; Hashiguchi, T.; Yamakuchi, M.; Goto, M.; Inoue, K.; Yamada, S.; Ijiri, K.; Matsunaga, S.; Nakajima, T.; Komiya, S.; Maruyama, I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48 (4), 971-981, 10.1002/art.10859
108. Hou, C.; Zhao, H.; Liu, L.; Li, W.; Zhou, X.; Lv, Y.; Shen, X.; Liang, Z.; Cai, S.; Zou, F. High mobility group protein b1 (hmgb1) in asthma: Comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol. Med. 2011, 17 (7-8), 807-815, 10.2119/molmed.2010.00173
109. Wu, T.; Zhang, W.; Yang, G.; Li, H.; Chen, Q.; Song, R.; Zhao, L. Hmgb1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review. Oncotarget. 2016, 7 (31), 50417-50427, 10.18632/oncotarget.10413
110. Yan, X. X.; Lu, L.; Peng, W. H.; Wang, L. J.; Zhang, Q.; Zhang, R. Y.; Chen, Q. J.; Shen, W. F. Increased serum hmgb1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009, 205 (2), 544-548, 10.1016/j.atherosclerosis.2008.12.016
111. Ding, J. W.; Zheng, X. X.; Zhou, T.; Tong, X. H.; Luo, C. Y.; Wang, X. A. Hmgb1modulates the treg/th17 ratio in atherosclerotic patients. J. Atheroscler. Thromb. 2016, 23 (6), 737-745, 10.5551/jat.31088
112. Nin, J. W.; Ferreira, I.; Schalkwijk, C. G.; Jorsal, A.; Prins, M. H.; Parving, H. H.; Tarnow, L.; Rossing, P.; Stehouwer, C. D. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study. Diabetologia 2012, 55 (9), 2489-2493, 10.1007/s00125-012-2622-1
113. Devaraj, S.; Dasu, M. R.; Park, S. H.; Jialal, I. Increased levels of ligands of toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52 (8), 1665-1668, 10.1007/s00125-009-1394-8
114. Wang, H.; Qu, H.; Deng, H. Plasma hmgb-1 levels in subjects with obesity and type 2 diabetes: A cross-sectional study in china. PLoS One 2015, 10 (8), e0136564, 10.1371/journal.pone.0136564
115. Chen, Y.; Qiao, F.; Zhao, Y.; Wang, Y.; Liu, G. Hmgb1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose. Int. J. Clin. Exp. Pathol. 2015, 8 (6), 6683-6691
116. Huang, Y. Y.; Su, W.; Zhu, Z. W.; Tang, L.; Hu, X. Q.; Zhou, S. H.; Fang, Z. F.; Li, J. Elevated serum hmgb1 in pulmonary arterial hypertension secondary to congenital heart disease. Vasc. Pharmacol. 2016, 85, 66-72, 10.1016/j.vph.2016.08.009
117. Ito, Y.; Torii, Y.; Ohta, R.; Imai, M.; Hara, S.; Kawano, Y.; Matsubayashi, T.; Inui, A.; Yoshikawa, T.; Nishimura, N.; Ozaki, T.; Morishima, T.; Kimura, H. Increased levels of cytokines and high-mobility group box 1 are associated with the development of severe pneumonia, but not acute encephalopathy, in 2009 h1n1 influenza-infected children. Cytokine 2011, 56 (2), 180-187, 10.1016/j.cyto.2011.07.016
118. Angus, D. C.; Yang, L.; Kong, L.; Kellum, J. A.; Delude, R. L.; Tracey, K. J.; Weissfeld, L. Circulating high-mobility group box 1 (hmgb1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit. Care Med. 2007, 35 (4), 1061-1067, 10.1097/01.CCM.0000259534.68873.2A
119. Ueno, H.; Matsuda, T.; Hashimoto, S.; Amaya, F.; Kitamura, Y.; Tanaka, M.; Kobayashi, A.; Maruyama, I.; Yamada, S.; Hasegawa, N.; Soejima, J.; Koh, H.; Ishizaka, A. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 2004, 170 (12), 1310-1316, 10.1164/rccm.200402-188OC
120. Ingels, C.; Derese, I.; Wouters, P. J.; Van den Berghe, G.; Vanhorebeek, I. Soluble rage and the rage ligands hmgb1 and s100a12 in critical illness: Impact of glycemic control with insulin and relation with clinical outcome. Shock 2015, 43 (2), 109-116, 10.1097/SHK.0000000000000278
121. Wang, L. J.; Lu, L.; Zhang, F. R.; Chen, Q. J.; De Caterina, R.; Shen, W. F. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur. J. Heart Failure 2011, 13 (4), 440-449, 10.1093/eurjhf/hfq231
122. Liu, T.; Zhang, D. Y.; Zhou, Y. H.; Han, Q. F.; Wang, L. H.; Wu, L.; Yao, H. C. Increased serum hmgb1 level may predict the fatal outcomes in patients with chronic heart failure. Int. J. Cardiol. 2015, 184, 318-320, 10.1016/j.ijcard.2015.02.088
123. Goldstein, R. S.; Gallowitsch-Puerta, M.; Yang, L.; Rosas-Ballina, M.; Huston, J. M.; Czura, C. J.; Lee, D. C.; Ward, M. F.; Bruchfeld, A. N.; Wang, H.; Lesser, M. L.; Church, A. L.; Litroff, A. H.; Sama, A. E.; Tracey, K. J. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25 (6), 571-574, 10.1097/01.shk.0000209540.99176.72
124. Momonaka, H.; Hasegawa, S.; Matsushige, T.; Inoue, H.; Kajimoto, M.; Okada, S.; Nakatsuka, K.; Morishima, T.; Ichiyama, T. High mobility group box 1 in patients with 2009 pandemic h1n1 influenza-associated encephalopathy. Brain Dev. 2014, 36 (6), 484-488, 10.1016/j.braindev.2013.07.001
125. Palone, F.; Vitali, R.; Cucchiara, S.; Pierdomenico, M.; Negroni, A.; Aloi, M.; Nuti, F.; Felice, C.; Armuzzi, A.; Stronati, L. Role of hmgb1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014, 20 (8), 1448-1457, 10.1097/MIB.0000000000000113
126. McDonnell, M.; Liang, Y.; Noronha, A.; Coukos, J.; Kasper, D. L.; Farraye, F. A.; Ganley-Leal, L. M. Systemic toll-like receptor ligands modify b-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis. 2011, 17 (1), 298-307, 10.1002/ibd.21424
127. Ilmakunnas, M.; Tukiainen, E. M.; Rouhiainen, A.; Rauvala, H.; Arola, J.; Nordin, A.; Makisalo, H.; Hockerstedt, K.; Isoniemi, H. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008, 14 (10), 1517-1525, 10.1002/lt.21573
128. Chimenz, R.; Lacquaniti, A.; Colavita, L.; Chirico, V.; Fede, C.; Buemi, M.; Fede, C. High mobility group box 1 and tumor growth factor beta: Useful biomarkers in pediatric patients receiving peritoneal dialysis. Renal Failure 2016, 38 (9), 1370-1376, 10.1080/0886022X.2016.1216711
129. Zakiyanov, O.; Kriha, V.; Vachek, J.; Zima, T.; Tesar, V.; Kalousova, M. Placental growth factor, pregnancy-associated plasma protein-a, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: A cross sectional study. BMC Nephrol. 2013, 14, 245, 10.1186/1471-2369-14-245
130. Kruger, B.; Krick, S.; Dhillon, N.; Lerner, S. M.; Ames, S.; Bromberg, J. S.; Lin, M.; Walsh, L.; Vella, J.; Fischereder, M.; Kramer, B. K.; Colvin, R. B.; Heeger, P. S.; Murphy, B. T.; Schroppel, B. Donor toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (9), 3390-3395, 10.1073/pnas.0810169106
131. Bruchfeld, A.; Qureshi, A. R.; Lindholm, B.; Barany, P.; Yang, L.; Stenvinkel, P.; Tracey, K. J. High mobility group box protein-1 correlates with renal function in chronic kidney disease (ckd). Mol. Med. 2008, 14 (3-4), 109-115, 10.2119/2007-00107.Bruchfeld
132. Zamora, R.; Vodovotz, Y.; Mi, Q.; Barclay, D.; Yin, J.; Horslen, S.; Rudnick, D.; Loomes, K. M.; Squires, R. H. Data-driven modeling for precision medicine in pediatric acute liver failure. Mol. Med. 2016, 22, 821-829, 10.2119/molmed.2016.00183
133. Basta, G.; Del Turco, S.; Navarra, T.; Lee, W. M. Acute Liver Failure Study, G. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure. Liver Transpl. 2015, 21 (6), 847-854, 10.1002/lt.24129
134. Majumdar, M.; Ratho, R.; Chawla, Y.; Singh, M. P. High levels of circulating hmgb1 as a biomarker of acute liver failure in patients with viral hepatitis e. Liver Int. 2013, 33 (9), 1341-1348, 10.1111/liv.12197
135. Andersson, A.; Covacu, R.; Sunnemark, D.; Danilov, A. I.; Dal Bianco, A.; Khademi, M.; Wallstrom, E.; Lobell, A.; Brundin, L.; Lassmann, H.; Harris, R. A. Pivotal advance: Hmgb1 expression in active lesions of human and experimental multiple sclerosis. J. Leukocyte Biol. 2008, 84 (5), 1248-1255, 10.1189/jlb.1207844
136. Arrigo, T.; Chirico, V.; Salpietro, V.; Munafo, C.; Ferrau, V.; Gitto, E.; Lacquaniti, A.; Salpietro, C. High-mobility group protein b1: A new biomarker of metabolic syndrome in obese children. Eur. J. Endocrinol. 2013, 168 (4), 631-638, 10.1530/EJE-13-0037
137. Yasuda, T.; Ueda, T.; Takeyama, Y.; Shinzeki, M.; Sawa, H.; Nakajima, T.; Ajiki, T.; Fujino, Y.; Suzuki, Y.; Kuroda, Y. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006, 33 (4), 359-363, 10.1097/01.mpa.0000236741.15477.8b
138. Xu, G. F.; Guo, M.; Tian, Z. Q.; Wu, G. Z.; Zou, X. P.; Zhang, W. J. Increased of serum high-mobility group box chromosomal protein 1 correlated with intestinal mucosal barrier injury in patients with severe acute pancreatitis. World J. Emerg Surg. 2014, 9, 61, 10.1186/1749-7922-9-61
139. Zhu, L.; Zhang, Z.; Zhang, L.; Shi, Y.; Qi, J.; Chang, A.; Gao, J.; Feng, Y.; Yang, X. Hmgb1-rage signaling pathway in severe preeclampsia. Placenta 2015, 36 (10), 1148-1152, 10.1016/j.placenta.2015.08.006
140. Ueno, T.; Ikeda, T.; Ikeda, K.; Taniuchi, H.; Suda, S.; Yeung, M. Y.; Matsuno, N. Hmgb-1 as a useful prognostic biomarker in sepsis-induced organ failure in patients undergoing pmx-dhp. J. Surg. Res. 2011, 171 (1), 183-190, 10.1016/j.jss.2009.11.708
141. Hatada, T.; Wada, H.; Nobori, T.; Okabayashi, K.; Maruyama, K.; Abe, Y.; Uemoto, S.; Yamada, S.; Maruyama, I. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb. Haemostasis 2005, 94 (5), 975-979, 10.1160/TH05-05-0316
142. Yu, H.; Qi, Z.; Zhao, L.; Shao, R.; Fang, Y.; Li, C. Prognostic value of dynamic monitoring of cellular immunity and hmgb1 in severe sepsis: Delayed chronic inflammation may be the leading cause of death in late severe sepsis. Clin. Lab. 2016, 62 (12), 2379-2385, 10.7754/Clin.Lab.2016.160530
143. Bae, J. S. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Arch. Pharmacal Res. 2012, 35 (9), 1511-1523, 10.1007/s12272-012-0901-5
144. Lu, M.; Yu, S.; Xu, W.; Gao, B.; Xiong, S. Hmgb1 promotes systemic lupus erythematosus by enhancing macrophage inflammatory response. J. Immunol. Res. 2015, 2015, 946748, 10.1155/2015/946748
145. Li, J.; Xie, H.; Wen, T.; Liu, H.; Zhu, W.; Chen, X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J. Rheumatol. 2010, 37 (4), 766-775, 10.3899/jrheum.090663
146. Ma, C. Y.; Jiao, Y. L.; Zhang, J.; Yang, Q. R.; Zhang, Z. F.; Shen, Y. J.; Chen, Z. J.; Zhao, Y. R. Elevated plasma level of hmgb1 is associated with disease activity and combined alterations with ifn-alpha and tnf-alpha in systemic lupus erythematosus. Rheumatol. Int. 2012, 32 (2), 395-402, 10.1007/s00296-010-1636-6
147. Zickert, A.; Palmblad, K.; Sundelin, B.; Chavan, S.; Tracey, K. J.; Bruchfeld, A.; Gunnarsson, I. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res. Ther. 2012, 14 (1), R36, 10.1186/ar3747
148. Papatheodorou, A.; Stein, A.; Bank, M.; Sison, C. P.; Gibbs, K.; Davies, P.; Bloom, O. High-mobility group box 1 (hmgb1) is elevated systemically in persons with acute or chronic traumatic spinal cord injury. J. Neurotrauma 2017, 34 (3), 746-754, 10.1089/neu.2016.4596
149. Wang, X. W.; Karki, A.; Zhao, X. J.; Xiang, X. Y.; Lu, Z. Q. High plasma levels of high mobility group box 1 is associated with the risk of sepsis in severe blunt chest trauma patients: A prospective cohort study. J. Cardiothorac Surg. 2014, 9, 133, 10.1186/s13019-014-0133-5
150. Wang, K. Y.; Yu, G. F.; Zhang, Z. Y.; Huang, Q.; Dong, X. Q. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin. Chim. Acta 2012, 413 (21-22), 1737-1741, 10.1016/j.cca.2012.07.002
151. Au, A. K.; Aneja, R. K.; Bell, M. J.; Bayir, H.; Feldman, K.; Adelson, P. D.; Fink, E. L.; Kochanek, P. M.; Clark, R. S. Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome c predict outcome after pediatric traumatic brain injury. J. Neurotrauma 2012, 29 (11), 2013-2021, 10.1089/neu.2011.2171
152. Li, L.; Ling, Y.; Huang, M.; Yin, T.; Gou, S. M.; Zhan, N. Y.; Xiong, J. X.; Wu, H. S.; Yang, Z. Y.; Wang, C. Y. Heparin inhibits the inflammatory response induced by lps and hmgb1 by blocking the binding of hmgb1 to the surface of macrophages. Cytokine 2015, 72 (1), 36-42, 10.1016/j.cyto.2014.12.010
153. Opal, S. M.; Laterre, P. F.; Francois, B.; LaRosa, S. P.; Angus, D. C.; Mira, J. P.; Wittebole, X.; Dugernier, T.; Perrotin, D.; Tidswell, M.; Jauregui, L.; Krell, K.; Pachl, J.; Takahashi, T.; Peckelsen, C.; Cordasco, E.; Chang, C. S.; Oeyen, S.; Aikawa, N.; Maruyama, T.; Schein, R.; Kalil, A. C.; Van Nuffelen, M.; Lynn, M.; Rossignol, D. P.; Gogate, J.; Roberts, M. B.; Wheeler, J. L.; Vincent, J. L. Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: The access randomized trial. JAMA 2013, 309 (11), 1154-1162, 10.1001/jama.2013.2194
154. Perrin-Cocon, L.; Aublin-Gex, A.; Sestito, S. E.; Shirey, K. A.; Patel, M. C.; Andre, P.; Blanco, J. C.; Vogel, S. N.; Peri, F.; Lotteau, V. Tlr4 antagonist fp7 inhibits lps-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci. Rep. 2017, 7, 40791, 10.1038/srep40791
155. Hennessy, E. J.; Parker, A. E.; O'Neill, L. A. Targeting toll-like receptors: Emerging therapeutics?. Nat. Rev. Drug Discovery 2010, 9 (4), 293-307, 10.1038/nrd3203
156. Park, S.; Shin, H. J.; Shah, M.; Cho, H. Y.; Anwar, M. A.; Achek, A.; Kwon, H. K.; Lee, B.; Yoo, T. H.; Choi, S. Tlr4/md2 specific peptides stalled in vivo lps-induced immune exacerbation. Biomaterials 2017, 126, 49-60, 10.1016/j.biomaterials.2017.02.023
157. Ahn, S. I.; Kim, J. S.; Gu, G. J.; Shin, H. M.; Kim, A. Y.; Shim, H. J.; Kim, Y. J.; Koh, K. O.; Mang, J. Y.; Kim, D. Y.; Youn, H. S. Suppression of toll-like receptor 4 dimerization by 1-[5-methoxy-2-(2-nitrovinyl)phenyl]pyrrolidine. Arch. Pharm. (Weinheim, Ger.) 2016, 349 (10), 785-790, 10.1002/ardp.201600159
158. Aletaha, S.; Haddad, L.; Roozbehkia, M.; Bigdeli, R.; Asgary, V.; Mahmoudi, M.; Mirshafiey, A. M2000 (beta-d-mannuronic acid) as a novel antagonist for blocking the tlr2 and tlr4 downstream signalling pathway. Scand J. Immunol. 2017, 85 (2), 122-129, 10.1111/sji.12519
159. Perez-Regidor, L.; Zarioh, M.; Ortega, L.; Martin-Santamaria, S. Virtual screening approaches towards the discovery of toll-like receptor modulators. Int. J. Mol. Sci. 2016, 17 (9), 1508, 10.3390/ijms17091508
160. Billod, J. M.; Lacetera, A.; Guzman-Caldentey, J.; Martin-Santamaria, S. Computational approaches to toll-like receptor 4 modulation. Molecules 2016, 21 (8), 994, 10.3390/molecules21080994
161. Sabbagh, M. N.; Agro, A.; Bell, J.; Aisen, P. S.; Schweizer, E.; Galasko, D. Pf-04494700, an oral inhibitor of receptor for advanced glycation end products (rage), in alzheimer disease. Alzheimer Dis. Assoc. Disord. 2011, 25 (3), 206-212, 10.1097/WAD.0b013e318204b550
162. Panza, F.; Seripa, D.; Solfrizzi, V.; Imbimbo, B. P.; Lozupone, M.; Leo, A.; Sardone, R.; Gagliardi, G.; Lofano, L.; Creanza, B. C.; Bisceglia, P.; Daniele, A.; Bellomo, A.; Greco, A.; Logroscino, G. Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer's disease patients. Expert Opin. Emerging Drugs 2016, 21 (4), 377-391, 10.1080/14728214.2016.1241232
163. Deane, R.; Singh, I.; Sagare, A. P.; Bell, R. D.; Ross, N. T.; LaRue, B.; Love, R.; Perry, S.; Paquette, N.; Deane, R. J.; Thiyagarajan, M.; Zarcone, T.; Fritz, G.; Friedman, A. E.; Miller, B. L.; Zlokovic, B. V. A multimodal rage-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of alzheimer disease. J. Clin. Invest. 2012, 122 (4), 1377-1392, 10.1172/JCI58642
164. Kokkola, R.; Li, J.; Sundberg, E.; Aveberger, A. C.; Palmblad, K.; Yang, H.; Tracey, K. J.; Andersson, U.; Harris, H. E. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003, 48 (7), 2052-2058, 10.1002/art.11161
165. Yang, H.; Ochani, M.; Li, J.; Qiang, X.; Tanovic, M.; Harris, H. E.; Susarla, S. M.; Ulloa, L.; Wang, H.; DiRaimo, R.; Czura, C. J.; Wang, H.; Roth, J.; Warren, H. S.; Fink, M. P.; Fenton, M. J.; Andersson, U.; Tracey, K. J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (1), 296-301, 10.1073/pnas.2434651100
166. Arumugam, T.; Ramachandran, V.; Gomez, S. B.; Schmidt, A. M.; Logsdon, C. D. S100p-derived rage antagonistic peptide reduces tumor growth and metastasis. Clin. Cancer Res. 2012, 18 (16), 4356-4364, 10.1158/1078-0432.CCR-12-0221
167. Barnay-Verdier, S.; Gaillard, C.; Messmer, M.; Borde, C.; Gibot, S.; Marechal, V. Pca-elisa: A sensitive method to quantify free and masked forms of hmgb1. Cytokine 2011, 55 (1), 4-7, 10.1016/j.cyto.2011.03.011
168. Antoine, D. J.; Williams, D. P.; Kipar, A.; Jenkins, R. E.; Regan, S. L.; Sathish, J. G.; Kitteringham, N. R.; Park, B. K. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 2009, 112 (2), 521-531, 10.1093/toxsci/kfp235
169. Shin, J. U.; Noh, J. Y.; Lee, J. H.; Lee, W. J.; Yoo, J. S.; Kim, J. Y.; Kim, H.; Jung, I.; Jin, S.; Lee, K. H. In vivo relative quantitative proteomics reveals hmgb1 as a downstream mediator of oestrogen-stimulated keratinocyte migration. Exp Dermatol. 2015, 24 (6), 478-480, 10.1111/exd.12713
170. Lundback, P.; Stridh, P.; Klevenvall, L.; Jenkins, R. E.; Fischer, M.; Sundberg, E.; Andersson, U.; Antoine, D. J.; Harris, H. E. Characterization of the inflammatory properties of actively released hmgb1 in juvenile idiopathic arthritis. Antioxid. Redox Signaling 2016, 24 (12), 605-619, 10.1089/ars.2014.6039
171. Yang, L. S.; Xu, X. E.; Liu, X. P.; Jin, H.; Chen, Z. Q.; Liu, X. H.; Wang, Y.; Huang, F. P.; Shi, Q. Itraq-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p. J. Proteomics 2012, 77, 480-491, 10.1016/j.jprot.2012.09.028
172. Vidova, V.; Spacil, Z. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. Anal. Chim. Acta 2017, 964, 7-23, 10.1016/j.aca.2017.01.059
173. Trenchevska, O.; Nelson, R. W.; Nedelkov, D. Mass spectrometric immunoassays in characterization of clinically significant proteoforms. Proteomes 2016, 4 (1), 13, 10.3390/proteomes4010013
174. Anderson, N. L. The clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56 (2), 177-185, 10.1373/clinchem.2009.126706
175. Jones, C. W.; Handler, L.; Crowell, K. E.; Keil, L. G.; Weaver, M. A.; Platts-Mills, T. F. Non-publication of large randomized clinical trials: Cross sectional analysis. BMJ. 2013, 347, f6104, 10.1136/bmj.f6104
176. Ross, J. S.; Tse, T.; Zarin, D. A.; Xu, H.; Zhou, L.; Krumholz, H. M. Publication of nih funded trials registered in clinicaltrials.Gov: Cross sectional analysis. BMJ. 2011, 344, d7292, 10.1136/bmj.d7292